Annual report pursuant to Section 13 and 15(d)

Income Taxes (Tables)

v3.8.0.1
Income Taxes (Tables)
12 Months Ended
Dec. 31, 2017
Income Tax Disclosure [Abstract]  
Schedule of components of deferred tax assets and liabilities
    2017     2016  
Deferred tax assets:                
Net operating losses carry forward   $ 30,826,534     $ 38,874,255  
Share-based compensation     3,731,413       8,081,711  
Research & Development/Orphan Drug Credits     6,324,998       830,085
Others     11,369       16,329  
Less: valuation allowance     (40,894,314 )     (47,802,380 )
                 
Deferred tax assets, net   $ -     $ -  
Schedule of difference between income tax provision and U.S federal statutory rate
    For the year ended  
    December 31, 2017     December 31, 2016     December 31, 2015  
                                                 
Federal income taxes at 34%   $ (9,044,420 )     (34.0 )%   $ (8,269,386 )     (34.0 )%   $ (7,148,607 )     (34.0 )%
State income taxes     (1,940,945 )     (7.3 )%     973,547       4.0 %                
Change in Federal statutory rate     17,939,714       67.4 %     -       - %     -       - %
Deferred true-up     3,090,815       11.8 %     (10,511,380 )     (43.3 )%     1,104,763       5.2 %
Research and Development/Orphan Drug Tax Credit     (3,029,074 )     (11.4 )%     (141,769 )     (0.6 )%     -       - %
Unrealized derivative gain/loss     (120,870 )     (0.5 )%     (956,840 )     (3.9 )%                
Other     12,845       0.0 %     13,632       0.1 %     -       - %
Change in valuation allowance     (6,908,065 )     (26.0 )%     18,892,196       77.7 %     6,043,844       28.8 %
                                                 
Provision for income tax   $ -       -     $ -       -     $ -       -